Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR<i>δ</i>-AMPK-PGC-1<i>α</i> Pathway in Dyslipidemic Conditions

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Ingredient</td><td class="align_center">mg</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Normal control diet</td><td class="align_center">990</td></tr><tr><td class="align_left">Cholesterol</td><td class="align_center">10</td></tr><tr><td class="align_left">Total</td><td class="align_center">1000</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

BioMed Research International

tab2

Table 2

Table 2: Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR<i>δ</i>-AMPK-PGC-1<i>α</i> Pathway in Dyslipidemic Conditions 

Table 2 | Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions 